Autopsy report · NCT03742323

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

“Because of low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

PETHEMA Foundation

Sponsor type

University, hospital or other

Conditions

Acute Lymphoblastic Leukemia

Interventions

Idelalisib

Participants

6

Sites

12

Countries

Spain

Trials that died the same way

• Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke
  “Because of low recruitment rates” (94% match in meaning)
• Antidepressant Effects of TS-161 in Treatment-Resistant Depression
  “due to low recruitment” (94% match in meaning)
• Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
  “due to lack of recruitment” (88% match in meaning)
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
  “Due to Poor Recruitment” (86% match in meaning)
• Whole-body Vibration Physiotherapy in Kidney Transplantation
  “Due to low recruitment rate” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.